Abstract
Cyclodepsipeptides show an interesting spectrum of biological activity. Members of this new class of potential drugs may also serve as lead compounds for more pharmacologically potent and toxicologically safe derivatives. Some of these natural products and (semi-)synthetic derivatives have already been evaluated in clinical trials. A common feature of cyclodepsipeptides is their ionophoric properties. However, their pharmacologically relevant action does not seem to correlate with this feature; rather it is based on interactions with distinct cellular compartments and signal transduction pathways. Cyclodepsipeptides, which are currently being evaluated in clinical trials, are used in refractory cancer therapy, usually in combination with other cytotoxic drugs. A series of cyclooctadepsipeptides, however, shows a completely different spectrum of biological activity, namely, potent anthelmintic properties. A number of cyclodepsipeptides have been well characterized in vitro and in vivo, and interesting modes of action, such as antiplasmodial, antiviral, insecticidal, cytotoxic, and antiproliferative properties have been observed. Whether these natural products will be of benefit for patients must be evaluated in clinical trials. Recently, a number of cyclodepsipeptides from marine sponges, bacteria and fungi have been identified. Subsequent structural determination revealed unique structural features within some of these compounds. It was suggested that the cyclic depsipeptide structure is important for the biological activity because the linear homologues were inactive. The scope of activity of these newly isolated natural products spans a range from cytoprotective activity against HIV-1 infection, growth inhibitory effects toward cancer cells, and antimycobacterial, and antimalarial activity.
Keywords: Cyclodepsipeptides, kahalalide F, depsipeptide, aplidin, PF1022A, natural compounds
Current Medicinal Chemistry
Title: Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Volume: 16 Issue: 9
Author(s): R. Lemmens-Gruber, M. R. Kamyar and R. Dornetshuber
Affiliation:
Keywords: Cyclodepsipeptides, kahalalide F, depsipeptide, aplidin, PF1022A, natural compounds
Abstract: Cyclodepsipeptides show an interesting spectrum of biological activity. Members of this new class of potential drugs may also serve as lead compounds for more pharmacologically potent and toxicologically safe derivatives. Some of these natural products and (semi-)synthetic derivatives have already been evaluated in clinical trials. A common feature of cyclodepsipeptides is their ionophoric properties. However, their pharmacologically relevant action does not seem to correlate with this feature; rather it is based on interactions with distinct cellular compartments and signal transduction pathways. Cyclodepsipeptides, which are currently being evaluated in clinical trials, are used in refractory cancer therapy, usually in combination with other cytotoxic drugs. A series of cyclooctadepsipeptides, however, shows a completely different spectrum of biological activity, namely, potent anthelmintic properties. A number of cyclodepsipeptides have been well characterized in vitro and in vivo, and interesting modes of action, such as antiplasmodial, antiviral, insecticidal, cytotoxic, and antiproliferative properties have been observed. Whether these natural products will be of benefit for patients must be evaluated in clinical trials. Recently, a number of cyclodepsipeptides from marine sponges, bacteria and fungi have been identified. Subsequent structural determination revealed unique structural features within some of these compounds. It was suggested that the cyclic depsipeptide structure is important for the biological activity because the linear homologues were inactive. The scope of activity of these newly isolated natural products spans a range from cytoprotective activity against HIV-1 infection, growth inhibitory effects toward cancer cells, and antimycobacterial, and antimalarial activity.
Export Options
About this article
Cite this article as:
Lemmens-Gruber R., Kamyar R. M. and Dornetshuber R., Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process, Current Medicinal Chemistry 2009; 16 (9) . https://dx.doi.org/10.2174/092986709787581761
DOI https://dx.doi.org/10.2174/092986709787581761 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Thyroid Ultrasound and Other Imaging Procedures in the Pediatric Age
Current Pediatric Reviews Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Allelic Variations in CYP2D6 Gene and Susceptibility to Cervical Cancer
Drug Metabolism Letters Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Current Clinical Pharmacology Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy